Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 8:15:1759720X231192315.
doi: 10.1177/1759720X231192315. eCollection 2023.

Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis

Oliver FitzGerald  1 , Frank Behrens  2 , Anne Barton  3 , Heidi Bertheussen  4 , Bruno Boutouyrie-Dumont  5 , Laura Coates  6 , Owen Davies  7 , Maarten de Wit  8 , Filippo Fagni  9   10 , Carl S Goodyear  11 , Robert Gurke  12 , Lisa Hahnefeld  12 , Christine Huppertz  5 , Vassilios Ioannidis  13 , Mark Ibberson  13 , Arnon Katz  14 , Maximilian Klippstein  2 , Michaela Koehm  2 , Shimon Korish  15 , Sina Mackay  16 , David A Martin  17 , Denis O'Sullivan  18 , Khadijah Patel  3 , Stefan Rueping  16 , Georg Schett  9   10 , Klaus Scholich  12 , Jochen M Schwenk  19 , Stefan Siebert  11 , David Simon  9   10 , Arani Vivekanantham  6 , Stephen R Pennington  1
Affiliations
Review

Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis

Oliver FitzGerald et al. Ther Adv Musculoskelet Dis. .

Abstract

Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for better short-term and long-term outcomes.

Keywords: HIPPOCRATES; IMI; diagnosis; multi-omics; patient outcomes; psoriasis; psoriatic arthritis.

Plain language summary

Improving outcomes in Psoriatic Arthritis Psoriatic Arthritis (PsA) is a form of arthritis which is found in approximately 30% of people who have the skin condition, Psoriasis. Frequently debilitating and progressive, achieving a good outcome for a person with PsA is made difficult by late diagnosis, disease clinical features and in many cases, failure to adequately control features of inflammation. Research studies from individual centres have certainly contributed to our understanding of why people develop PsA but to adequately address the major areas of unmet need, multi-centre, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient representative organisations (see appendix). In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. The participation of patient research partners in all stages of the work of HIPPOCRATES is highlighted. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for improvements in short-term and long-term outcomes.

PubMed Disclaimer

Conflict of interest statement

OF has received grants from AbbVie, Bristol Myers Squibb, Janssen, Eli-Lilly, Novartis, Pfizer and UCB. DS has received grants from AbbVie, Janssen, Eli-Lilly and Novartis. SK is an employee of and has stocks or stock options in Bristol Myers Squibb. LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli-Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB. FB and MK have received grants/research support from AbbVie, Amgen, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli-Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB. AB has received grants/research support from Pfizer, Bristol Myers Squibb, Galapagos and Schiper Medicine and received speaker fees from Chugai-Roche. AV, MKl and JMS – no conflicts of interest to declare. CSG has received grants/research support from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Eli-Lilly, Istesso, Janssen, MedAnnex, MiroBio, Pfizer, UCB; worked as a consultant for AstraZeneca, Bristol Myers Squibb, Janssen, MedAnnex, MiroBio; and has been paid as a speaker for AbbVie and UCB. BBD was an employee and then a consultant of Novartis Pharma AG. CH is an employee of Novartis Pharma AG. SS has received institutional research support from Amgen (previously Celgene), Boehringer Ingelheim, Bristol Myers Squibb, Eli-Lilly, GSK, Janssen and UCB; consultancy/speaker fees from AbbVie, Amgen, AstraZeneca, Eli-Lilly, GSK, Janssen and UCB. MdW: Over the last 3 years Stichting Tools has received fees for lectures or consultancy provided by Maarten de Wit from Celgene, Eli-Lilly, Pfizer and UCB.

Figures

Figure 1.
Figure 1.
HIPPOCRATES project overview. Eight interconnected work packages that embed and involve patients, clinicians, primary care practitioners, regulators, small and medium enterprises (SMEs) and relevant pharmaceutical company partners to: (1) combine the most extensive and well-studied cohorts of patients with PsA across Europe; (2) establish and maintain a Europe-wide library of clinical biosamples relevant to PsA; (3) discover, evaluate and validate biomarker signatures that address the key unmet needs in psoriatic disease and (4) evaluate biomarker signatures to develop diagnostic algorithms for clinical implementation.
See this image and copyright information in PMC

References

    1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376: 2095–2096. - PubMed
    1. FitzGerald O, Ogdie A, Chandran V, et al.. Psoriatic arthritis. Nat Rev Dis Prim 2021; 7: 59. - PubMed
    1. Jadon DR, Stober C, Pennington SR, et al.. Applying precision medicine to unmet clinical needs in psoriatic disease. Nat Rev Rheumatol 2020; 16: 609–627. - PubMed
    1. FitzGerald O, Pennington SR. HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis. Nat Rev Rheumatol 2022; 18: 123–124. - PubMed
    1. Taylor W, Gladman D, Helliwell P, et al.. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–2673. - PubMed